Relmada Therapeutics, Inc. (RLMD) Stock Forecast
RLMD analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.75 / 5 from 4 analysts
- Price target
- $10.75 average of analyst targets
- Upside to target
- +246.8% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.14
- 52-week range
- $2.10 – $7.86
RLMD analyst ratings
4 analystsNumber of analysts at each rating.
RLMD price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
RLMD earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.14 | −$0.16 | −$0.14 | −$0.30 | +51.7% | 4 |
| Current fiscal year (2026) | −$0.41 | −$0.41 | −$0.41 | −$1.10 | +62.8% | 1 |
| Next fiscal year (2027) | −$0.41 | −$0.41 | −$0.41 | −$0.41 | 0.0% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
RLMD revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | — | 4 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 4 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 4 |
RLMD EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
RLMD EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.20 | −$0.21 | −$0.21 | −$0.15 | −$0.14 | −29.3% | 1 up · 0 down |
| Current fiscal year (2026) | −$0.36 | −$0.36 | −$0.36 | −$0.36 | −$0.41 | +13.9% | 0 up · 1 down |
| Next fiscal year (2027) | −$0.46 | −$0.46 | −$0.46 | −$0.46 | −$0.41 | −10.9% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
RLMD earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; RLMD beat in 5 of 12.
What analysts expect from RLMD
4 analysts cover Relmada Therapeutics; their consensus rating is strong buy (4.75 on a 1–5 scale, where 5 is a strong buy). The average price target is $10.75, 246.8% above the latest close of $3.10. Analysts expect earnings of −$0.41 per share for 2026, +62.8% from a year earlier. For 2027 the average estimate is −$0.41 per share. Relmada Therapeutics beat the EPS estimate in 5 of the last 12 quarters.
Related: RLMD income statement, RLMD key metrics, RLMD chart. See the RLMD stock overview for the latest quote and news.
RLMD forecast FAQ
What is Relmada Therapeutics's price target?
The average analyst price target for Relmada Therapeutics is $10.75, 246.8% above the latest close of $3.10.
Is Relmada Therapeutics a buy, hold or sell?
Of 4 analysts covering Relmada Therapeutics, 3 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Relmada Therapeutics's EPS forecast?
Analysts forecast −$0.41 per share for 2026 (range −$0.41 to −$0.41); for 2027 the estimate is −$0.41.
When does Relmada Therapeutics report earnings?
Relmada Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 after the market closes; the EPS estimate is $-0.14.
Does Relmada Therapeutics usually beat earnings estimates?
Relmada Therapeutics reported EPS at or above the analyst estimate in 5 of the last 12 quarters.